Download - AWMF

Weitere Magazine

Empfehlungen

Info

Leitlinien für Diagnostik und Therapie in der Neurologie Perez MC, Buot WL, Mercadodanguilan C et al. Stable remissions in myasthenia gravis. Neurology 1981; 31: 32– 37 Pevzner A, Schoser B, Peters K et al. Anti-LPR autoantibodies in AChR- and MuSK-seronegative myasthenia gravis. J Neurol 2012; 259: 427–435 Pinching AJ, Peters DK, Davis JN. Remission of myasthenia gravis following plasma-exchange. Lancet 1976; 2: 1373–1376 Ponseti JM, Azem J, Fort JM et al. Long-term results of tacrolimus in cyclosporine- and prednisone-dependent myasthenia gravis. Neurology 2005; 64: 1641–1643 Ponseti JM, Gamez J, Azem J et al. Tacrolimus for myasthenia gravis – a clinical study of 212 patients. In: Kaminski HJBRJ, ed. Myasthenia Gravis and Related Disorders: 11th International Conference; 2008: 254–263 Punga AR, Flink R, Askmark H et al. Cholinergic neuromuscular hyperactivity in patients with myasthenia gravis seropositive for muskle antibody. Muscle Nerve 2006; 34: 111–115 Qureshi AI, Choudhry MA, Akbar MS et al. Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis. Neurology 1999; 52: 629–632 Reddy AR, Backhouse OC. "Ice-on-eyes", a simple test for myasthenia gravis presenting with ocular symptoms. Pract Neurol 2007; 7: 109–111 Roberts A, Perera S, Lang B et al. Para-neoplastic myasthenic syndrome IgG inhibits Ca-452+ flux in a human small cell carcinoma line. Nature 1985; 317: 737–739 Roberts PF, Venuta F, Rendina E et al. Thymectomy in the treatment of ocular myasthenia gravis. J Thorac Cardiovasc Surg 2001; 122: 562–568 Robertson NP, Deans J, Compston DAS. Myasthenia gravis: a population based epidemiological study in Cambridgeshire, England. J Neurol Neurosurg Psychiatry 1998; 65: 492–496 Ronager J, Ravnborg M, Hermansen I et al. Immunoglobulin treatment versus plasma exchange in patients with chronic moderate to severe myasthenia gravis. Art Organs 2001; 25: 967–973 Rückert JC, Gellert K, Müller JM. Operative technique for thoracoscopic thymectomy. Surg Endosc 1999; 13: 943– 946 Sabbagh MN, Garza JS, Patten B. Thoracoscopic thymectomy in patients 2wyth myasthenia gravis. Muscle Nerve 1995; 18: 1475–1477 Samtleben W, Besinger UA, Toyka KV et al. Plasma-eseparation in myasthenia gravis – new method of rapid plasma-exchange. Klin Wschr 1980; 58: 47–49 Sanders DB, Hart IK, Mantegazza R et al. An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. Neurology 2008; 71: 400–406 Sanders DB, Massey JM, Sanders LL et al. A randomized trial of 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome. Neurology 2000; 54: 603–607 Schmitt J, Loehrer PJ. The role of chemotherapy in advanced thymoma. J Thorac Oncol 2010; 5: 357–360 Schneider-Gold C, Gajdos P, Toyka KV et al. Corticosteroids for myasthenia gravis. Cochrane Database Syst Rev 2005; 2: CD002828 Schumm F, Stohr M. Accessory nerve stimulation in the assessment of myasthenia gravis. Muscle Nerve 1984; 7: 147–151 Seybold ME, Drachman DB. Gradually increasing doses of prednisone in myasthenia gravis – reducing hazards of treatment. N Engl J Med 1974; 290: 81–84 Shigemoto K, Kubo S, Maruyama N et al. Induction of myasthenia by immunization against muscle-specific kinase. J Clin Invest 2006; 116: 1016–1024 Singman EL, Matta NS, Silbert DI. Use of the Cogan lid twitch to identify myasthenia gravis. J Neuro-Ophthalmol 2011; 31: 239–240 Skeie GO, Apostolski S, Evoli A et al. Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol 2010; 17: 893–902 Slesak G, Melms A, Gerneth F et al. Late-onset myasthenia gravis – follow-up of 113 patients diagnosed after age 60. In: Richman DP, ed. Myasthenia Gravis and Related Diseases: Disorders of the Neuromuscular Junction. New York: Ann.N.Y. Acad. Sci.; 1998: 777–80 Soliven B, Rezania K, Gundogdu B et al. Terbutaline in myasthenia gravis: a pilot study. J Neurol Sci 2009; 277: 150–154 Sommer N, Sigg B, Melms A et al. Ocular myasthenia gravis: Response to long term immunosuppressive treatment. J Neurol Neurosurg Psychiatry 1997; 62: 156–162 Somnier FE. Increasing incidence of late-onset anti-AChR antibody seropositive myasthenia gravis. Neurology 2005; 65: 928–930 Stangel M, Gold R. Einsatz intravenöser Immunglobuline in der Neurologie. Ein evidenzbasierter Konsens: Update 2010. Nervenarzt 2011; 82 : 415–416 Streib EW, Rothner AD. Eaton-Lambert myasthenic syndrome – long-term treatment of 3 patients with prednisone. Ann Neurol 1981; 10: 448–453 Ströbel P, Bauer A, Puppe B et al. Tumor recurrence and survival in patients treated for thymomas and thymic squamous cell carcinomas: A retrospective analysis. J Clin Oncol 2004; 22: 1501–1509 Tackenberg B, Hemmer B, Oertel WH et al. Immunosuppressive treatment of ocular myasthenia gravis. Biodrugs 2001; 15: 369–378 Tada M, Shimohata T, Tada M et al. Long-terms therapeutic efficacy and safety of low-dose tacrolimus (FK506) for 28
Leitlinien für Diagnostik und Therapie in der Neurologie myasthenia gravis. J Neurol Sci 2006; 247: 17–20 Thomas CE, Mayer SA, Gungor Y et al. Myasthenic crisis: Clinical features, mortality, complications, and risk factors for prolonged intubation. Neurology 1997; 48: 1253–1260 Tindall RSA, Phillips JT, Rollins JA et al. A clinical therapeutic trial of cyclosporine in myasthenia gravis. Ann NY Acad Sci 1993; 681: 539–551 Tindall RSA, Rollins JA, Phillips JT et al. Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. N Engl J Med 1987; 316: 719–724 Toyka KV. Ptosis in myasthenia gravis: Extended fatigue and recovery bedside test. Neurology 2006; 67: 1524 Toyka KV, Becker T, Fateh-Moghadam A et al. Die Bedeutung von Antikörpern gegen Acetylcholin-Rezeptoren für die Diagnostik der Myasthenia gravis. Klin Wschr 1979; 57: 937–942 Toyka KV, Drachman DB, Pestronk A. et al. Myasthenia gravis passive transfer from man to mouse. Science 1975; 190: 397–399 Toyka KV, Heininger K. Acetylcholin-Rezeptor-Antikörper in der Diagnostik der Myasthenia gravis. Untersuchungen bei 406 gesicherten Fällen. Dtsch Med Wschr 1986; 111: 1435–1439 Toyka KV, Müllges W. Myasthenia gravis and Lambert-Eaton-myasthenic-syndrome. In: Hacke W et al. (eds). Neuro Critical Care. Berlin 1994: 807–815 Toyka MV, Schneider-Gold C. Oculomotor signs in Lambert-Eaton myasthenic syndrome – coincidence with myasthenia gravis. Ann Neurol 2003; 54: 135–136 Vernino S, Salomao DR, Habermann TM et al. Primary CNS lymphoma complicating treatment of myasthenia gravis with mycophenolate mofetil. Neurology 2005; 65: 639–641 Vincent A, Clover L, Buckley C et al. Survey UKMG. Evidence of underdiagnosis of myasthenia gravis in older people. J Neurol Neurosurg Psychiatry 2003; 74: 1105–1108 Voltz RD, Albrich WC, Nagele A et al. Paraneoplastic myasthenia gravis: Detection of anti-MGT30 (titin) antibodies predicts thymic epithelial tumor. Neurology 1997; 49: 1454–1457 Vrolix K, Fraussen J, Molenaar PC et al. The auto-antigen repertoire in myasthenia gravis. Autoimmunity 2010; 43: 380–400 Walker MB. Case showing the effect of prostigmin on myasthenia gravis. Proc Royal Soc Med 1935; 28: 759–761 Wirtz PW, Sotodeh M, Nijnuis M et al. Difference in distribution of muscle weakness between myasthenia gravis and the Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 2002; 73: 766–768 Wirtz PW, Verschuuren JJ, van Dijk JG et al. Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert-Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study. Clin Pharmacol Ther 2009; 86: 44–48 Wirtz PW, Bradshaw J, Wintzen AR et al. Associated autoimmune diseases in patients with the Lambert Eaton myasthenic syndrome and their families. J Neurol 2004; 251: 1255–1259 Witte AS, Cornblath DR, Parry GJ et al. Azathioprine in the treatment of myasthenia gravis. Ann Neurol 1984; 15: 602–604 Witte AS, Cornblath DR, Schatz NJ et al. Monitoring azathioprine therapy in myasthenia gravis. Neurology 1986; 36: 1533–1534 Wright CD. Management of thymomas. Crit Rev Oncol Hematol 2008; 65: 109–120 Wylam ME, Anderson PM, Kuntz NL et al. Successful treatment of refractory myasthenia gravis using rituximab: A pediatric case report. J Pediatrics 2003; 143: 674–677 Yeh JH, Chiu HC. Comparison between double-filtration plasmapheresis and immunoadsorption plasmapheresis in the treatment of patients with myasthenia gravis. J Neurology 2000; 247: 510–513 Yim APC, Kay RLC, Ho JKS. Video-assisted thoracoscopic thymectomy for myasthenia gravis. Chest 1995; 108: 1440–1443 Zaja F, Russo D, Fuga G et al. Rituximab for myasthenia gravis developing after bone marrow transplant. Neurology 2000; 55: 1062–1063 Zeitler H, Ulrich-Merzenich G, Hoffmann L et al. Long-term effects of a multimodal approach including immunoadsorption for the treatment of myasthenic crisis. Art Organs 2006; 30: 597–605 Zinman L, Ng E, Bril V. IV immunoglobulin in patients with myasthenia gravis – a randomized controlled trial. Neurology 2007; 68: 837–841 Zinman L, Thoma J, Kwong JC et al. Safety of influenza vaccination in patients with myasthenia gravis: a population-based study. Muscle Nerve 2009; 40: 947–951 Aus: Hans-Christoph Diener, Christian Weimar (Hrsg.) Leitlinien für Diagnostik und Therapie in der Neurologie Herausgegeben von der Kommission "Leitlinien" der Deutschen Gesellschaft für Neurologie Thieme Verlag, Stuttgart, September 2012 >Buch bei Amazon bestellen 29
Seite 1 und 2: Leitlinien für Diagnostik und Ther
Seite 27: Leitlinien für Diagnostik und Ther

Download - AWMF

Sie wollen auch ein ePaper? Erhöhen Sie die Reichweite Ihrer Titel.

Template löschen?

Als Template speichern?